The estimated Net Worth of Robert A Copeland is at least $2.68 Milion dollars as of 6 June 2017. Robert Copeland owns over 2,500 units of Epizyme Inc stock worth over $50,036 and over the last 11 years Robert sold EPZM stock worth over $2,628,526.
Robert has made over 29 trades of the Epizyme Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert exercised 2,500 units of EPZM stock worth $8,850 on 6 June 2017.
The largest trade Robert's ever made was exercising 38,400 units of Epizyme Inc stock on 2 June 2014 worth over $19,584. On average, Robert trades about 10,486 units every 38 days since 2013. As of 6 June 2017 Robert still owns at least 34,038 units of Epizyme Inc stock.
You can see the complete history of Robert Copeland stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: